Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patients. [PDF]
Wenzel M +11 more
europepmc +1 more source
Reply to: Revisiting Radium-223 in Oligometastatic Castration-Sensitive Prostate Cancer: RAVENS Trial Insights. [PDF]
Tran PT, Wang JH, Tang C, Kiess AP.
europepmc +1 more source
Fracture risk and survival outcomes of radium-223 therapy for bone metastases in mCRPC and the modulatory role of bone-protective therapy: a systematic review and meta-analysis. [PDF]
Xiao M, Liu F, Duan H.
europepmc +1 more source
Impact of timing of radium‑223 administration on the survival of patients with bone metastatic castration‑resistant prostate cancer. [PDF]
Makita K +8 more
europepmc +1 more source
Brazilian profile of Radium-223 in metastatic prostate cancer: a multicentric, retrospective study. [PDF]
Souza S +27 more
europepmc +1 more source
Recurrent Extraneural Metastatic Medulloblastoma in an Adult Presenting With a Superscan and Treated With Radium-223. [PDF]
Mou B, Cruz-Lim EM.
europepmc +1 more source
Exhalation of Rn-219 by patients treated with Radium-223. [PDF]
Wanke C +3 more
europepmc +1 more source
Outcomes and Factors Associated with Completion of Radium-223 Therapy. [PDF]
Liu RF, Juwara L, Ferrario C, Probst SM.
europepmc +1 more source
Prostate cancer – Therapy with radium-223 [PDF]
Ana Emília, Brito +4 more
openaire +2 more sources
Prognostic factors for overall survival in patients with metastatic castration-resistant prostate cancer treated with radium-223: a meta-analysis of real-world evidence. [PDF]
Song B, Shao H, He Y, Zhu X, Qin P.
europepmc +1 more source

